$0.07
(Market cap
$252 Mln
Revenue (TTM)
$66 Mln
P/E Ratio
--
P/B Ratio
20.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-2.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-6.9
-
Debt to Equity
-1
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
111,700,347
10 Years Aggregate
CFO
€-54.72 Mln
EBITDA
€-23.80 Mln
Net Profit
€-316.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Innate Pharma S.A. ADS - ADR
| 27.4 | 25.3 | 29.7 | 6.2 | -6.7 | -8.0 | -- |
|
BSE Sensex
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Innate Pharma S.A. ADS - ADR
| -4.9 | -34.1 | -24.9 | -18.2 | 11.5 | -36.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Innate Pharma S.A. ADS - ADR
|
2.2 | 252.4 | 2.8 | -49.2 | -86.4 | 764.8 | -- | 20.1 |
| 23.3 | 12,469.9 | 19,427.2 | 937.8 | 9.6 | 5.1 | 12.4 | 0.9 | |
| 28.0 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 4.9 | 1,105.5 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 45.2 | 2,212.5 | 29.6 | -24.0 | -- | 31.9 | -- | 65.0 | |
| 6.6 | 660.0 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.9 |
Shareholding Pattern
View DetailsAbout Innate Pharma S.A. ADS - ADR
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials... for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France. Read more
-
Co-Founder, Interim CEO & Chairman of Executive Board
Dr. Herve Brailly Ph.D.
-
Co-Founder, Interim CEO & Chairman of Executive Board
Dr. Herve Brailly Ph.D.
-
Headquarters
Marseille
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Innate Pharma S.A. ADS - ADR
What is the current share price of Innate Pharma SA ADS - ADR Today?
The share price of Innate Pharma SA ADS - ADR is $2.23 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Innate Pharma SA ADS - ADR has given a return of -6.75% in the last 3 years.
What is the current PB & PE ratio of Innate Pharma SA ADS - ADR?
Since, TTM earnings of Innate Pharma SA ADS - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-3.25 |
-7.37 |
2024 |
-3.01 |
16.84 |
2023 |
-29.81 |
4.35 |
2022 |
-5.15 |
5.52 |
2021 |
-6.87 |
3.38 |
What is the 52 Week High and Low of Innate Pharma SA ADS - ADR?
The 52-week high and low of Innate Pharma SA ADS - ADR are Rs 2.71 and Rs 1.17 as of 28-Aug-2026.
What is the market cap of Innate Pharma SA ADS - ADR?
Innate Pharma SA ADS - ADR has a market capitalisation of $ 252 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Innate Pharma SA ADS - ADR?
Before investing in Innate Pharma SA ADS - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.